Leading-edge technologies in the fight against cancer
We are a next generation radiopharmaceutical company, taking cancer head on.
Thank you! Your submission has been received!
POINT Biopharma Announces FRONTIER Trial-in-Progress Poster Presentation at ASCO
PNT2004 program’s phase 1 FRONTIER trial design to be presented. Abstract to be released at 5:00 PM ET, May 25th. Poster to be available starting at 9:00 AM ET, June 3rd.
POINT Biopharma Reports First Quarter 2023 Financial Results and Provides Business Highlights
U.S. FDA granted Fast Track designation for 177Lu-PNT2002 for the treatment of mCRPC in April 2023. Announces $10 million strategic investment in commercial-scale alpha-emitting isotope manufacturer, Ionetix Alpha Corp.